GRAIL, Inc. (GRAL)
NASDAQ: GRAL · Real-Time Price · USD
49.82
-0.41 (-0.82%)
At close: Mar 9, 2026, 4:00 PM EDT
49.47
-0.35 (-0.70%)
After-hours: Mar 9, 2026, 7:57 PM EDT
GRAIL Revenue
In the year 2025, GRAIL had annual revenue of $147.17M with 17.18% growth. GRAIL had revenue of $43.60M in the quarter ending December 31, 2025, with 13.97% growth.
Revenue (ttm)
$147.17M
Revenue Growth
+17.18%
P/S Ratio
13.65
Revenue / Employee
$147,172
Employees
1,000
Market Cap
2.01B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| RadNet | 2.04B |
| Sotera Health Company | 1.16B |
| Neogen | 880.32M |
| NeoGenomics | 727.33M |
| OPKO Health | 606.88M |
| Veracyte | 517.15M |
| GeneDx Holdings | 427.54M |
| Twist Bioscience | 391.56M |
GRAL News
- 4 days ago - Levi & Korskinsky, LLP: Grail (GRAL) Guided to 2030 Cash Runway While Key Trial Risk Went Unaddressed - GlobeNewsWire
- 7 days ago - GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 13 days ago - GRAIL to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 14 days ago - GRAIL Stock Tumbles — National Health Service Galleri Trial To Blame - Benzinga
- 14 days ago - 'Holy Grail' Honus Wagner card sells for over $5M as family auctions it from grandfather's collection - Fox Business
- 17 days ago - This once-hot cancer-detection company's stock got cut in half after a failed trial - Market Watch
- 17 days ago - Grail shares plunge after major cancer screening trial misses main goal - Reuters
- 17 days ago - Grail Stock Plunges 50% After Earnings. But It's These Test Results That Are to Blame. - Barrons